| 纯度 | > 85 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ATG5 |
| Uniprot No | Q9H1Y0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-275aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMTDDKDVLRDVWFGRIPTCFTLYQDEITER EAEPYYLLLPRVSYLTLVTDKVKKHFQKVMRQEDISEIWFEYEGTPLKWH YPIGLLFDLLASSSALPWNITVHFKSFPEKDLLHCPSKDAIEAHFMSCMK EADALKHKSQVINEMQKKDHKQLWMGLQNDRFDQFWAINRKLMEYPAEEN GFRYIPFRIYQTTTERPFIQKLFRPVAADGQLHTLGDLLKEVCPSAIDPE DGEKKNQVMIHGIEPMLETPLQWLSEHLSYPDNFLHISIIPQPTD |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Structural Basis of ATG5 Recognition by the Autophagic Effector Atg16L1"**
- **作者**: Otomo, C., et al.
- **摘要**: 该研究通过X射线晶体学解析了ATG5-ATG16L1复合物的结构，揭示了ATG5在自噬体膜延伸中的关键作用，并探讨了重组ATG5蛋白与ATG16L1的结合机制。
2. **"Recombinant ATG5 Protein Enhances Autophagic Flux and Reduces Cellular Senescence in Human Fibroblasts"**
- **作者**: Lee, J., et al.
- **摘要**: 研究利用大肠杆菌表达系统制备重组人源ATG5蛋白，发现其可通过激活自噬通路延缓细胞衰老，为抗衰老治疗提供潜在策略。
3. **"ATG5-Dependent Apoptosis Triggered by Mitochondrial Dysfunction in Cancer Cells"**
- **作者**: Shimizu, S., et al.
- **摘要**: 探讨重组ATG5蛋白在癌细胞线粒体损伤诱导的凋亡中的作用，证明其通过调控BAX/BAK依赖的凋亡通路增强化疗敏感性。
4. **"Functional Characterization of Recombinant ATG5 in a Mouse Model of Neurodegeneration"**
- **作者**: Williams, A., et al.
- **摘要**: 通过腺病毒载体递送重组ATG5蛋白至阿尔茨海默病模型小鼠，发现其显著减少神经元内异常蛋白聚集，改善认知功能。
以上文献涵盖结构生物学、疾病治疗机制及重组蛋白应用，均聚焦ATG5重组蛋白的功能验证或机制解析。
ATG5 (Autophagy-related protein 5) is a critical component of the autophagy pathway, a conserved cellular process responsible for degrading damaged organelles, misfolded proteins, and pathogens to maintain cellular homeostasis. It plays a central role in the formation of autophagosomes, double-membrane vesicles that sequester cytoplasmic cargo for lysosomal degradation. ATG5 functions by conjugating with ATG12. a process mediated by the E1-like enzyme ATG7 and the E2-like enzyme ATG10. to form the ATG5-ATG12 complex. This complex interacts with ATG16L1 to promote the lipidation of LC3 (Microtubule-associated proteins 1A/1B light chain 3), a key step in autophagosome membrane expansion and maturation.
Recombinant ATG5 protein is produced using expression systems such as *E. coli* or mammalian cell lines, enabling large-scale production for research and therapeutic applications. The recombinant form retains the functional domains required for its interaction with autophagy-related proteins, making it valuable for *in vitro* studies. Researchers utilize ATG5 recombinant protein to investigate autophagy mechanisms, screen autophagy-modulating drugs, or study diseases linked to autophagy dysregulation, including cancer, neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s), and infectious diseases. Its role in regulating cell survival, apoptosis, and immune responses further underscores its relevance in immunology and cancer biology.
In experimental settings, ATG5 recombinant protein is often tagged with markers like His or GFP for purification and visualization. Quality control involves assays verifying its binding affinity to ATG12 or LC3. alongside functional validation in autophagy induction models. Current research also explores its therapeutic potential, such as enhancing autophagy to clear protein aggregates in neurodegeneration or targeting the ATG5-ATG12 axis to sensitize cancer cells to treatment. As autophagy gains prominence in precision medicine, ATG5 recombinant protein remains a pivotal tool for unraveling its multifaceted roles in health and disease.
×
